Trethera is a leading preclinical-stage biopharmaceutical company that specializes in precise targeting of nucleotide metabolism for the treatment of cancers and autoimmune diseases. Led by an experienced drug development team and founded by renowned UCLA faculty, Trethera focuses on developing innovative medical solutions. Their flagship product, TRE-515, is a groundbreaking first-in-class inhibitor of deoxycytidine kinase (dCK).

This multidimensional drug holds immense potential in effectively combatting autoimmune diseases and cancers. What sets Trethera apart is their unique therapeutic approach. By targeting multiple pathways and using rationally-designed combinations of drugs, they aim to improve efficacy and address the limitations of previous single agent therapies.

With a strong management team, dedicated board of directors, and esteemed scientific founders, Trethera is committed to developing groundbreaking treatments that make a significant impact on patient lives. Choose Trethera for cutting-edge, precise, and innovative solutions in the fight against cancer and autoimmune diseases